On May 23, 2019 VBL Therapeutics (Nasdaq: VBLT), reported the upcoming presentation of final results from the Phase 2 study of VB-111 in ovarian cancer at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2019 Annual Meeting, to be held May 31 – June 4, 2019 in Chicago, Illinois (Press release, VBL Therapeutics, MAY 23, 2019, View Source [SID1234536552]). An additional presentation at ASCO (Free ASCO Whitepaper) will focus on analysis of VB-111 MRI data from Phase 2 and Phase 3 studies in recurrent GBM and the potential of VB-111 in this indication. VBL will also give a company presentation at the 2019 BIO International Convention, to be held June 3-6, 2019 in Philadelphia.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2019 ASCO (Free ASCO Whitepaper) Annual Meeting – Presentation Details

1. Title: Ofranergene obadenovec (VB-111) in platinum resistant ovarian cancer
Abstract: 5542
Session Type: Poster Session
Session Title: Gynecologic Cancer
Date: June 1, 2019
Time: 1:15 PM – 4:15 PM CDT
Location: Hall A
Poster Board: #365
Presenter: Richard T. Penson, MD, MRCP, Massachusetts General Hospital

2. Title: Quantitative radiographic analysis of phase II and III trials in recurrent glioblastoma treated with VB-111 with or without bevacizumab or bevacizumab monotherapy.
Abstract: 2018
Session Type: Poster Session
Session: Central Nervous System Tumors
Date: June 2, 2019
Time: 8:00 AM – 11:00 AM CDT
Location: Hall A
Poster Board: #207
Presenter: Benjamin M. Ellingson, PhD, MS. University of California Los Angeles

3. Title: Quantitative radiographic analysis of phase II and III trials in recurrent glioblastoma treated with VB-111 with or without bevacizumab or bevacizumab monotherapy.
Abstract: 2018
Session Type: Poster Discussion Session
Session: Central Nervous System Tumors
Date: June 2, 2019
Time: 4:30 PM – 6:00 PM CDT
Location: S404
Poster Board: #207
Presenter: Benjamin M. Ellingson, PhD, MS. University of California Los Angeles

2019 BIO International Convention – Presentation Details

Date: June 4, 2019
Time: 3:30 pm EDT
Presentation Room: Theater 2
Location: Philadelphia Convention Center
Webcast: 2019 BIO International Convention Webcast

About VB-111 (ofranergene obadenovec)
VB-111, a potential first-in-class anticancer therapeutic candidate, is the Company’s lead oncology product currently being studied in the OVAL potential-registration Phase 3 pivotal trial for ovarian cancer (ClinicalTrials.gov Identifier: NCT03398655). VB-111 has received orphan drug designation in both the US and Europe, and fast track designation in the US for prolongation of survival in patients with rGBM. In addition, VB-111 successfully demonstrated proof-of-concept and survival benefit in Phase 2 clinical trials in radioiodine-refractory thyroid cancer and recurrent platinum-resistant ovarian cancer (NCT01711970). VB-111 has received an Orphan Designation for the treatment of ovarian cancer from the European Commission.